Kinaxis Partners With Exelixis to Advance Supply Chain Planning for Its Cancer Drug Portfolio

Kinaxis Partners With Exelixis to Advance Supply Chain Planning for Its Cancer Drug Portfolio
Kinaxis helping to improve transparency and mitigate risk to commercialise new medicines through concurrent planning

London, UK, 26th August 2021 – Kinaxis® Inc. (TSX: KXS), a leader in supply chain management software, today announced that Exelixis, Inc. has selected Kinaxis to evolve its global supply chain planning capabilities. Exelixis will leverage RapidStart, the accelerated Kinaxis enterprise deployment methodology to reach time-to-value sooner.

An oncology-focused biotechnology company headquartered in Alameda, California, Exelixis is on a mission to help cancer patients recover stronger and live longer through the discovery, development and commercialisation of new medicines for difficult-to-treat cancers. Today, Exelixis has two commercially available cancer therapies used by patients worldwide. Exelixis works closely with contract manufacturers and identified the need for a supply chain solution to provide it with visibility, flexibility and collaboration capabilities.

Exelixis will deploy Kinaxis RapidResponse® and concurrent planning for supply, demand and inventory management using the RapidStart deployment methodology. With Kinaxis, Exelixis gains the ability to plan for every scenario and immediately see how changes affect the entire supply chain. This will enable the company to maximise its supply management approaches to continue to serve its customers to the highest standards.

“Interruptions in a pharmaceutical supply chain, even if seemingly small, can be costly to people’s health. It’s critical for companies like Exelixis to have the agility offered by concurrent planning to be able to predict, understand and react quickly to changes in time to make a difference,” said John Sicard, CEO of Kinaxis. “We are looking forward to working with Exelixis to build a more agile and transparent supply chain that will ultimately better serve those relying on the company’s medicines.”

About Kinaxis Inc.
Everyday volatility and uncertainty demand quick action. Kinaxis® delivers the agility to make fast, confident decisions across integrated business planning and the digital supply chain. People can plan better, live better and change the world. Trusted by innovative brands, we combine human intelligence with AI and concurrent planning to help companies plan for any future, monitor risks and opportunities and respond at the pace of change. Powered by an extensible, cloud-based platform, Kinaxis delivers industry-proven applications so everyone can know sooner, act faster and remove waste. For more Kinaxis news, visit Kinaxis.com or follow us on LinkedIn or Twitter.

Forward-Looking Statements
Certain statements in this release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements as to Kinaxis' growth opportunities and the potential benefits of, and demand for, Kinaxis' products and services. These statements are subject to certain assumptions, risks and uncertainties, including our view of the relative position of Kinaxis' products and services compared to competitive offerings in the industry. Readers are cautioned not to place undue reliance on such statements. Kinaxis' actual results, performance, achievements and developments may differ materially from the results, performance, achievements or developments expressed or implied by such statements. Risk factors that may cause the actual results, performance, achievements or developments of Kinaxis to differ materially from the results, performance, achievements or developments expressed or implied by such statements can be found in the public documents filed by Kinaxis with Canadian securities regulatory authorities. Kinaxis assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.